organization · Reporting owner
Versant Ventures V GP-GP (Canada), Inc.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | 10% owner | October 07, 2019 | October 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date October 07, 2019 · Filed October 07, 2019
Jointly reported with Versant V Luxco S.a r.l., Versant Ventures V, LLC, Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Venture Capital V, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,519,323 |
Last balance in matching sequence
After 2019-10-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-10-07 · Conversion · Acquired 1,993,658 · Balance 2,006,328 F1: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. Row 2 · 2019-10-07 · Conversion · Acquired 512,995 · Balance 2,519,323 F1: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 333,333 |
Reported balance
After 2019-10-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-10-07 · Purchase · Acquired 333,333 · Balance 333,333 F4: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-07 · Conversion · Disposed 1,993,658 · Balance 0 F1: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-07 · Conversion · Disposed 512,995 · Balance 0 F1: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l. F3: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.
F3: Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
F4: These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
F5: Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Repare Therapeutics Inc.
Report date June 03, 2022 · Filed June 07, 2022
Jointly reported with Versant Ventures V, LLC, Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Venture Capital V (Canada), LP, Versant Venture Capital V, L.P., Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Ventures V (Canada), L.P.
Section 16 reporting ended · disclosed 2022-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 2,344,451 |
Reported balance
After 2022-06-03 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-06-03 · Sale · Disposed 250,000 · Balance 2,344,451 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 1,464,875 |
Reported balance
After 2022-06-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2022-06-03 · Sale · Disposed 438,795 · Balance 1,464,875 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 44,065 |
Reported balance
After 2022-06-03 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2022-06-03 · Sale · Disposed 13,199 · Balance 44,065 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 48,776 |
Reported balance
After 2022-06-03 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2022-06-03 · Sale · Disposed 14,611 · Balance 48,776 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 111,484 |
Reported balance
After 2022-06-03 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2022-06-03 · Sale · Disposed 33,395 · Balance 111,484 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 850,560 |
Reported balance
After 2022-06-06 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2022-06-06 · Other · Disposed 614,315 · Balance 850,560 F7: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners. F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 25,587 |
Reported balance
After 2022-06-06 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2022-06-06 · Other · Disposed 18,478 · Balance 25,587 F10: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners. F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,322 |
Reported balance
After 2022-06-06 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2022-06-06 · Other · Disposed 20,454 · Balance 28,322 F12: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners. F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 64,731 |
Reported balance
After 2022-06-06 transaction · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · 2022-06-06 · Other · Disposed 46,753 · Balance 64,731 F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners. F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 10,099 |
Reported balance
After 2022-06-06 transaction · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · 2022-06-06 · Other · Acquired 10,099 · Balance 10,099 F16: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-06-06 transaction · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · 2022-06-06 · Other · Disposed 10,099 · Balance 0 F18: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 231,211 |
Reported balance
Holding disclosure · report date 2022-06-03 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 231,211 F19: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2022-06-06 transaction · row 12
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 7 · 2022-06-06 · Other · Acquired 132,692 · Balance 132,692 F8: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 9 · 2022-06-06 · Other · Acquired 3,992 · Balance 136,684 F11: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 11 · 2022-06-06 · Other · Acquired 4,419 · Balance 141,103 F13: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Row 12 · 2022-06-06 · Other · Disposed 141,103 · Balance 0 F14: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F3: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F4: Shares held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F5: Shares held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F6: Shares held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F7: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V to its partners.
F8: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
F9: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F10: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VAF V to its partners.
F11: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
F12: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VOAF I to its partners.
F13: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.
F14: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.
F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VVC V (Canada) to its partners.
F16: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).
F17: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
F18: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.
F19: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
Turnstone Biologics Corp.
Report date August 08, 2025 · Filed August 12, 2025
Jointly reported with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II, L.P.
Section 16 reporting ended · disclosed 2025-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V (Canada) LP | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-08-08 · Other · Disposed 207,486 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Ophthalmic Affiliates Fund I, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-08-08 · Other · Disposed 90,888 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Affiliates Fund V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-08-08 · Other · Disposed 82,006 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage II, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-08-08 · Other · Disposed 274,990 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2021 Filed Aug 9, 2021 20:44 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 152,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032177 · doc4.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 231,211 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021798 · doc4.xml · nonDerivative · entry 5 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F7 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021798 · doc4.xml · nonDerivative · entry 4 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,119 F6 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP. F7 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,128 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021798 · doc4.xml · nonDerivative · entry 3 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,128 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021798 · doc4.xml · nonDerivative · entry 2 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,128 F3 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I. F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:31 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021798 · doc4.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 383,282 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I"), to its partners. F2 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 3,473 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 10 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F15 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 3,473 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 9 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,473 F14 · kind: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F15 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 16,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 8 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 144,879 F12 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners pursuant to a Rule 10b5-1 trading plan. F13 · ownership.nature: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 48,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 7 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 6 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,528 F10 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 7,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 5 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,387 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: Shares held by VOAF I. VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 4 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,008 F7 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 6,355 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 3 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 57,264 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan. F6 · ownership.nature: Shares held by VAF V. VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 45,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 2 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,635 F3 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 211,277 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018685 · doc4.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,903,670 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 10 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F15 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 9 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 745 F14 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP. F15 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 8 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F12 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 7 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 751 F11 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I. F12 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 6 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 458,282 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F10 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 5 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its members. F7 · ownership.nature: Shares held by VV VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 4 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,176 F6 · kind: Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV VI. F7 · ownership.nature: Shares held by VV VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 3 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI, to its partners. F4 · ownership.nature: Shares held by VV VI. VV VI GP is the sole general partner of VV VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI. Each of VV VI GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 2 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,000 F3 · kind: Represents a change in the form of ownership of VV VI by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC VI. F4 · ownership.nature: Shares held by VV VI. VV VI GP is the sole general partner of VV VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI. Each of VV VI GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007140 · doc4.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,594,451 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("VVC VI"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 20 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F32 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F31 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 19 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 745 F30 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP. F31 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 18 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F29 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F28 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 17 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 751 F27 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I. F28 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 16 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 508,282 F25 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F26 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 15 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F24 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its members. F23 · ownership.nature: Shares held by VV VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 14 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,313 F22 · kind: Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV VI. F23 · ownership.nature: Shares held by VV VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 13 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F21 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI, to its partners. F20 · ownership.nature: Shares held by VV VI. VV VI GP is the sole general partner of VV VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI. Each of VV VI GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 12 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,000 F19 · kind: Represents a change in the form of ownership of VV VI by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC VI. F20 · ownership.nature: Shares held by VV VI. VV VI GP is the sole general partner of VV VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VV VI. Each of VV VI GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 11 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,894,451 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("VVC VI"), to its partners, pursuant to a Rule 10b5-1 trading plan. F18 · ownership.nature: Shares held by VVC VI. Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 10 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F15 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 9 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,328 F14 · kind: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F15 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 20,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 8 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 160,958 F12 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"), to its partners, pursuant to a Rule 10b5-1 trading plan. F13 · ownership.nature: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 60,472 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 7 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 6 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,472 F10 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 8,766 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 5 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 70,422 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: Shares held by VOAF I. VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 4 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,579 F7 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 7,919 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 3 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 63,619 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F6 · ownership.nature: Shares held by VAF V. VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 56,868 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 2 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,868 F3 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4 · ownership.direct: Shares held by VV V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:54 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 263,278 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004272 · doc4.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,114,947 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 01:16 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002407 · doc4.xml · nonDerivative · entry 20 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F32 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members. F31 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 01:16 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002407 · doc4.xml · nonDerivative · entry 19 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 745 F30 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP. F31 · ownership.nature: Shares held by VV I GP-GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 01:16 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002407 · doc4.xml · nonDerivative · entry 18 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F29 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners. F28 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 01:16 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002407 · doc4.xml · nonDerivative · entry 17 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 751 F27 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I. F28 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.